Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2023-12-01DOI: 10.46497/ArchRheumatol.2023.10042
Reyhan Yılmaz, Ahmet Murt, Iclal Gurses, Serdal Ugurlu
{"title":"A different presentation of tubulointerstitial nephritis and uveitis syndrome mimicking Sjögren's syndrome.","authors":"Reyhan Yılmaz, Ahmet Murt, Iclal Gurses, Serdal Ugurlu","doi":"10.46497/ArchRheumatol.2023.10042","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.10042","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9549
Maryam Rezazadeh, Mohammad Hasan Jokar, Seyedeh Mehrnaz Aghili, Zahra Mirfeizi, Mahmoud Mahmoudi, Negar Morovatdar, Kamila Hashemzadeh
{"title":"Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity.","authors":"Maryam Rezazadeh, Mohammad Hasan Jokar, Seyedeh Mehrnaz Aghili, Zahra Mirfeizi, Mahmoud Mahmoudi, Negar Morovatdar, Kamila Hashemzadeh","doi":"10.46497/ArchRheumatol.2023.9549","DOIUrl":"10.46497/ArchRheumatol.2023.9549","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the correlation between serum and urinary B cell-activating factor (BAFF) levels and systemic lupus erythematosus (SLE) disease activity.</p><p><strong>Patients and methods: </strong>This case-control study was conducted with 87 participants between December 2020 and September 2021. Sixty-two SLE patients who fulfilled the eligibility criteria were enrolled. SLE patients were categorized into active (n=34) and inactive (n=28) groups based on their Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores. The control group consisted of 25 healthy subjects. Serum and urine samples were collected for the measurement of BAFF levels. Finally, the relationship between these variables and SLE disease activity was investigated.</p><p><strong>Results: </strong>The mean age of active (SLEDAI-2K >4) and inactive (SLEDAI-2K ≤4) SLE patients and healthy individuals were 32.8±7.8, 32.5±6.8, and 31.7±7.8 years, respectively (p=0.62). The median serum BAFF (s-BAFF) and urinary BAFF (u-BAFF) in active lupus patients (10.4 [2.3] ng/mL and 8.2 [3.7] ng/mL, respectively) were significantly higher than in inactive lupus patients (6 (7.1) ng/mL and 1.7 (4.7) ng/mL, respectively; p<0.001) and the control group (3 (3.7) ng/mL and 1.6 (2.2) ng/mL, respectively; p<0.001). However, s-BAFF (p=0.07) and u-BAFF (p=0.43) did not significantly differ between the inactive group and the control group. A significant positive correlation was observed between s-BAFF (r=0.41 and p=0.001) and u-BAFF (r=0.78 and p<0.001) levels and the SLEDAI-2K score.</p><p><strong>Conclusion: </strong>There is a significant positive correlation between serum and urinary BAFF levels and SLE disease activity. Furthermore, significantly higher levels of s-BAFF and u-BAFF have been observed in patients with active lupus compared to inactive and healthy subjects, indicating a possible role for BAFF in the pathogenesis of SLE disease activity.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9829
Soyeon Kim, Hyeryeong Nam, Bora Lee, Kyung-Ann Lee, Kyung Seek Choi, Hyun-Sook Kim
{"title":"The effects of oligomeric proanthocyanidins on hydroxychloroquine-induced retinopathy as revealed by nationwide medical claim data for South Korea.","authors":"Soyeon Kim, Hyeryeong Nam, Bora Lee, Kyung-Ann Lee, Kyung Seek Choi, Hyun-Sook Kim","doi":"10.46497/ArchRheumatol.2023.9829","DOIUrl":"10.46497/ArchRheumatol.2023.9829","url":null,"abstract":"Although hydroxychloroquine (HCQ) is considered to be safe drug with antiinf lammatory, immunomodulatory, and antithrombotic effects,1,2 rare cases of permanent visual impairment.2,3 The prevalence of HCQ retinopathy is about 7.5% for more than five years, increasing after 20 years.4 Oligomeric proanthocyanidins (OPCs) are antioxidants and rich in a grape seed extract.5-7 The extract is effective in some patients with non-proliferative diabetic retinopathy.8,9 The extract may protect retinal cells by inhibiting the oxidative stressmediated apoptosis mediated by activation of the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway in patients with diabetic retinopathy.9 No study has explored whether the extract may protect against HCQ retinopathy.10","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2024-03-01DOI: 10.46497/ArchRheumatol.2023.10203
Maryam Ahmadi, Narjes Soleimanifar, Abdolrahman Rostamian, Maryam Sadr, Hanieh Mojtahedi, Abeda Mazari, Mohammad Hossein Nicknam, Sara Assadiasl
{"title":"Aryl hydrocarbon receptor gene expression in ankylosing spondylitis and its correlation with interleukin-17, RAR-related orphan receptor gamma t expression, and disease activity indices.","authors":"Maryam Ahmadi, Narjes Soleimanifar, Abdolrahman Rostamian, Maryam Sadr, Hanieh Mojtahedi, Abeda Mazari, Mohammad Hossein Nicknam, Sara Assadiasl","doi":"10.46497/ArchRheumatol.2023.10203","DOIUrl":"10.46497/ArchRheumatol.2023.10203","url":null,"abstract":"<p><strong>Objectives: </strong>Considering the role of T helper (Th)17 cells in the pathogenesis of ankylosing spondylitis (AS), the aim of this study was to determine the correlation between aryl hydrocarbon receptor (AHR) gene expression and the expression of Th17-related genes including interleukin (IL)-17 and RAR-related orphan receptor gamma t (RORγt) transcription factor.</p><p><strong>Patients and methods: </strong>Thirty patients with AS (26 males, 4 females; mean age: 36.1±8.1 years) and 30 age- and sex-matched healthy individuals (26 males, 4 females; mean age: 36.2±14.6 years) were recruited for the case-control study between June 2021 and January 2022. Ribonucleic acid (RNA) was extracted from peripheral blood cells and expression levels of AHR, IL-17, RORγt, and AHR repressor (AHRR) genes were evaluated using real-time polymerase chain reaction technique. The serum level of IL-17 was evaluated with enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>The results showed a nonsignificant elevation of AHR, IL-17, and RORγt gene expression in the patient group compared to the control. There was a direct correlation between AHR gene expression and IL-17 and RORγt genes and a negative correlation between AHR and AHRR expression. Moreover, AHR gene expression showed a weak correlation with disease activity indices, including Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Global Score, and Ankylosing Spondylitis Quality of Life. Moreover, the serum level of IL-17 was higher in AS patients compared to the healthy group (p=0.02).</p><p><strong>Conclusion: </strong>Upregulated expression of the AHR gene in ankylosing spondylitis and its correlation with IL-17 and ROR-γ t gene expression suggests that it could be a potential diagnostic and therapeutic target for AS.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2023-12-01DOI: 10.46497/ArchRheumatol.2023.10192
Marko Barešić, Lucija Šimunić, Goran Šukara, Miroslav Mayer, Branimir Anić
{"title":"Two sisters with one disease: Giant cell arteritis within one family.","authors":"Marko Barešić, Lucija Šimunić, Goran Šukara, Miroslav Mayer, Branimir Anić","doi":"10.46497/ArchRheumatol.2023.10192","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.10192","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2024-03-01DOI: 10.46497/ArchRheumatol.2023.10147
Ezgi Balkarlı, Elif Kıymet, Elif Böncüoğlu, Şahika Şahinkaya, Miray Yılmaz Çelebi, Hurşit Apa, Timur Meşe, Hasan Ağın, Süleyman Nuri Bayram, İlker Devrim
{"title":"The evaluation of the burden of multisystem inflammatory syndrome in children on health economics.","authors":"Ezgi Balkarlı, Elif Kıymet, Elif Böncüoğlu, Şahika Şahinkaya, Miray Yılmaz Çelebi, Hurşit Apa, Timur Meşe, Hasan Ağın, Süleyman Nuri Bayram, İlker Devrim","doi":"10.46497/ArchRheumatol.2023.10147","DOIUrl":"10.46497/ArchRheumatol.2023.10147","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the diagnostic tests and treatments applied in patients with multisystem inflammatory syndrome in children (MIS-C) and to determine the effect of the disease on health costs.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included 59 MIS-C patients (40 males, 19 females; mean age: 7.7±4.2 years; range, 4 months to 16.5 years) who were admitted and treated between April 1, 2020, and November 1, 2021. Demographic and clinical features with hospital costs and length of stay were retrospectively reviewed from the medical files and computerized system of the hospital. Direct medical care costs of items were calculated with the hospital perspective using a combination of microcosting technique (resource-based accounting method) and hospital list data. Cases were classified as mild, moderate, or severe, and the patients were divided into two groups: the mild group and the moderate-severe group. Classification was determined by the vasoactive inotropic score (VIS), degree of respiratory support, and evidence of organ damage.</p><p><strong>Results: </strong>The mean age of the cases in the mild group was 6.5±3.7 years, and the mean age of the cases in the moderate-severe group was 9.2±4.3 years. Of 59 patients, 19 (32.2%) were followed up in the pediatric intensive care unit. The median duration of hospitalization in the hospital was 8 (interquartile range: 7-12) days. The total cost of the patients hospitalized with the diagnosis of MIS-C during the study period was 849,242.93$, and the mean cost per patient was 14,393.94±9,631.92$. In the distribution of the total cost of hospitalization according to expenses, the highest rate was pharmacy and blood products (51.99%) and IVIG costs (43.99%). While the mean total cost per person was 13,682.87±8,799.63$ in mild cases, it was 16,433.82±9,440.02$ in moderate-severe cases, and no statistically significant relationship was found between the two groups (p>0.05). There was no difference in the mean cost per patient between the cases with and without heart, lung, kidney, or neurologic involvement and advanced respiratory support (p>0.05). There was a strong positive correlation between the total costs and age (r=0.883, n=59, p<0.0001), with increased amount of costs with increased age.</p><p><strong>Conclusion: </strong>In the study, no statistically significant correlation was found between the total cost of per person in the mild group and the moderate-severe group (p>0.05). This finding may be due to the wide use of IVIG in MIS-C treatment, in addition to low transfer rates to pediatric intensive care units due to high-flow nasal cannula usage.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-06-14eCollection Date: 2024-03-01DOI: 10.46497/ArchRheumatol.2023.10149
Min Cheng, Gaihuan Zheng, Lu Gao, Bihong Zhang
{"title":"The relationship between Mycoplasma and Kawasaki disease in pediatric patients: An updated systematic review and meta-analysis.","authors":"Min Cheng, Gaihuan Zheng, Lu Gao, Bihong Zhang","doi":"10.46497/ArchRheumatol.2023.10149","DOIUrl":"10.46497/ArchRheumatol.2023.10149","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to clarify the relationship between <i>Mycoplasma pneumoniae (M. pneumoniae)</i> and Kawasaki disease by conducting an updated systemic review and meta-analysis of published studies.</p><p><strong>Materials and methods: </strong>Studies mentioning <i>M. pneumoniae</i> and Kawasaki disease before October 2022 were included in this meta-analysis. The pooled prevalence was calculated, and the log odds ratio in the random effects model was applied to estimate the pooled prevalence of <i>M. pneumoniae</i> infection in pediatric patients with Kawasaki disease. In addition, the clinical parameters, such as hemoglobin and erythrocyte sedimentation rate, were analyzed. Six studies with a total of 1,859 pediatric patients with Kawasaki disease were enrolled. The focused outcome was the pooled prevalence and clinical parameters.</p><p><strong>Results: </strong>The pooled prevalence of <i>M. pneumoniae</i> infection was statistically significant in pediatric patients with Kawasaki disease. In addition, the values of hemoglobin and erythrocyte sedimentation rate were significantly different between <i>M. pneumoniae</i>-infected and non-<i>M. pneumoniae</i>-infected patients with Kawasaki disease. Other clinical parameters were not significantly different between <i>M. pneumoniae</i>-infected and non-<i>M. pneumoniae</i>-infected patients with Kawasaki disease.</p><p><strong>Conclusion: </strong>The results suggest that <i>M. pneumoniae</i> infection is significantly prevalent in pediatric patients with Kawasaki disease. The lower values of hemoglobin and erythrocyte sedimentation rate in <i>M. pneumoniae</i>-infected patients with Kawasaki disease might be needed to investigate further.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2023-02-03eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9695
Atak Karabacak, Rahşan İnan, Nesrin Şen
{"title":"Evaluation of peripheral nerve involvements in patients with familial Mediterranean fever.","authors":"Atak Karabacak, Rahşan İnan, Nesrin Şen","doi":"10.46497/ArchRheumatol.2023.9695","DOIUrl":"10.46497/ArchRheumatol.2023.9695","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to evaluate possible peripheral and autonomic nerve involvement in familial Mediterranean fever (FMF) patients with nerve conduction studies, sympathetic skin response (SSR) and RR interval variability (RRIV).</p><p><strong>Patients and methods: </strong>The comparative case series was conducted with 76 participants between November 2017 and December 2018. Forty-six FMF patients, [12 with amyloidosis (5 males, 7 females; mean age: 44.7±13.9 years) and 34 without amyloidosis (14 males, 20 females; mean age: 35.9±8.7 years)], and 30 healthy volunteers (11 males, 19 females; mean age: 38.4±10 years) were included in this study. Nerve conduction parameters, SSR latency and amplitude from palmar and plantar responses, and RRIV at rest and deep breathing were studied in all the subjects. Neuropathic symptoms of the patient group were evaluated using the survey of autonomic symptoms scale and the neuropathy disability score.</p><p><strong>Results: </strong>Nerve conduction studies of the patient group revealed polyneuropathy in seven (15.21%) patients and carpal tunnel syndrome in six (13.04%) patients. The mean amplitudes of SSR measured from the soles were significantly lower than the control group (p=0.041). The mean values of RRIV during rest and hyperventilation were lower in the patient group compared to the control group, but no statistically significant difference was found (p=0.484, p=0.341).</p><p><strong>Conclusion: </strong>We detected that the prevalence of carpal tunnel syndrome in our patient population (13.04%) was higher than in the general population. Most of the changes in the range of parameters of SSR and RRIV determined in the patient group did not reach statistical significance, suggesting subclinical dysautonomia in FMF patients.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mortality in a cohort of Egyptian systemic lupus erythematosus patients: A comparison with African, Arabic, and Mediterranean studies.","authors":"Sherif Gamal, Hanaa Rady, Nesreen Sobhy, Ibrahem Siam, Ahmed Soliman, Fatema Elgengehy","doi":"10.46497/ArchRheumatol.2023.9860","DOIUrl":"10.46497/ArchRheumatol.2023.9860","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to examine the frequency, causes, and predictors of mortality in a cohort of Egyptian systemic lupus erythematosus (SLE) patients and compare mortality causes and the survival rate in our cohort to African, Arabic, and Mediterranean studies.</p><p><strong>Patients and methods: </strong>In this retrospective study, a review of medical records of 563 SLE patients (516 females, 47 males; median of age: 32 [IQR: 26-38 years]; range, 14 to 63 years) fulfilling the 1997 American College of Rheumatology (ACR) criteria between January 2015 and December 2019 was done. The data extracted included demographic, clinical, and laboratory features, treatments used, disease activity as measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and damage index as measured by Systemic Lupus International Collaborating Clinics (SLICC) damage index. Causes of mortality were also reported.</p><p><strong>Results: </strong>Out of 563 reviewed medical records, 50 (8.9%) patients died. Infection (28%) and organ damage (18%) were the most commonly reported causes of death. Multivariate Cox regression analysis showed that patients with cardiac manifestations, renal failure, those receiving higher doses of either oral (in their last visit) or intravenous (higher cumulative pulse steroids) steroids were at increased risk of mortality (p=0.011, p<0.001, p=0.01, and p<0.001, respectively; 95% confidence intervals 7.2, 63.9, 1.2, and 1.09, respectively). The overall survival at 5, 10, 15, and 20 years was 96.6%, 93.3%, 91.0%, and 83.2%, respectively, and 56.2% at 25 years until the end of the follow-up.</p><p><strong>Conclusion: </strong>Cardiac manifestations, renal failure, and higher steroid doses were independent predictors of mortality in our cohort. As in most African countries, infection was the main cause of death in our study; however, the mortality rate and the five-year survival among our cohort were better than in African (sub-Saharan) countries and similar to Arabic and Mediterranean countries.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Archives of rheumatologyPub Date : 2022-12-30eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9790
Koray Ayar, Meliha Kasapoğlu Aksoy, Tülay Dilara Hattatoğlu, Büşra Yeşil
{"title":"Depression is the most significant independent predictor of fatigue in patients with primary Sjögren's syndrome.","authors":"Koray Ayar, Meliha Kasapoğlu Aksoy, Tülay Dilara Hattatoğlu, Büşra Yeşil","doi":"10.46497/ArchRheumatol.2023.9790","DOIUrl":"10.46497/ArchRheumatol.2023.9790","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to evaluate the level of fatigue and the relationship between mood, pain, fibromyalgia, insomnia, disease activity, and dryness with fatigue in primary Sjögren's syndrome (PSS) patients.</p><p><strong>Patients and methods: </strong>In this case-control study, the participants were recruited between January 2021 and July 2021. Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F), pain DETECT questionnaire, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Insomnia Severity Index (ISI) were administered to 50 PSS patients (48 females, 2 males; mean age: 48.9±10.8 years; median age: 47 years; range, 29 to 71 years) and 60 healthy controls (HCs; 57 females, 3 males; mean age: 49.8±8.4 years, median age: 52 years; range, 32 to 72 years). In addition, EULAR Sjögren's syndrome disease activity index (ESSPRI), EULAR Sjögren's Syndrome Patient Reported Index (ESSDAI), pain thresholds, Schirmer tests, and whole unstimulated salivary flow rate measurements were determined in PSS patients. Independent predictors of fatigue (fatigue subscale scores <30.5) were investigated by logistic regression analysis.</p><p><strong>Results: </strong>The frequency of fatigue in PSS patients and HCs was 54.0% and 8.3%, respectively. The rates of mood disturbance (BDI ≥11) in PSS patients with and without fatigue were 70.4% and 13.1%, respectively. BDI (Rho=-0.804), BAI (Rho=-0.586), ISI (Rho=-0.483), and ESSDAI (Rho=-0.345) were negatively correlated with the fatigue subscale score. Depression [Odds ratio (OR): 1.214, confidence interval (CI): 1.007-1.463], fibromyalgia (OR: 21.674, CI: 1.470-319.469), disease activity (OR: 1.440; CI: 1.005-2.065), and insomnia (OR: 1.223, CI: 1.003-1.4922) were identified as independent predictors of fatigue in PSS patients. It was determined that BD alone could predict fatigue by 84% in PSS patients.</p><p><strong>Conclusion: </strong>Depression can be a prominent predictor of fatigue in PSS patients. There is a need for studies evaluating the effect of antidepressant treatment approaches on fatigue accompanied by mood disturbance in PSS patients.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}